DS
DSS.US DSS Inc
- Market cap
- USD 5.27M
- P/E
- -
- P/B
- 1.67x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DSS.US undervalued?
Graham numberThe Graham number of DSS Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DSS Inc fundamental analysis
No fundamental analysis for DSS Inc yet.
DSS Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DSS Inc
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that foc…
Full company profileDSS Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DSS Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.2M | 18.7M | 18.5M | 15.6M | 15.4M | 20.3M | 28.4M | 25.9M | 19.1M | 20.8M | 15.4M |
| Gross Profit | 8.06M | 7.65M | 6.66M | 5.21M | 4.36M | 3.45M | -4.61M | 543K | -4.44M | -2.17M | -4.48M |
| Operating Income | -660K | -226K | -1.71M | -2.62M | -11.4M | -23.5M | -30.0M | -23.6M | -20.9M | -14.4M | -11.8M |
| EBITDA | 701K | 1.04M | 2.91M | -1.44M | 1.54M | -35.7M | -29.7M | -68.3M | -50.4M | -23.7M | -12.8M |
| Net Income | -950K | -578K | 1.46M | -2.89M | 1.90M | -33.1M | -59.8M | -60.6M | -46.9M | -23.9M | -20.3M |
| EPS | -2.18 | -1.20 | 2.60 | -61,468 | 6.31 | -13 | -11 | -8.67 | -6.63 | -2.66 | -2.03 |
| Balance Sheet | |||||||||||
| Total Assets | 18.5M | 17.4M | 15.3M | 20.1M | 91.9M | 283M | 249M | 153M | 106M | 67.6M | 65.2M |
| Total Liabilities | 15.2M | 12.6M | 7.71M | 7.84M | 15.4M | 84.5M | 92.2M | 70.0M | 73.7M | 58.9M | 60.9M |
| Shareholders' Equity | 3.28M | 4.79M | 7.57M | 12.3M | 73.1M | 162M | 126M | 83.2M | 20.2M | -832K | -4.12M |
| Cash & Short-term Investments | 5.87M | 4.19M | 2.32M | 1.10M | 5.18M | 56.6M | 19.3M | 6.62M | 11.4M | 6.21M | 3.28M |
| Total Debt | 6.45M | 6.35M | 2.44M | 3.39M | 2.44M | 60.1M | 66.8M | 62.8M | 64.1M | 43.1M | 36.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.47M | -1.37M | -1.38M | -5.34M | -6.15M | -8.81M | -27.0M | -19.2M | -9.08M | -9.13M | -3.97M |
| Capital Expenditure | 3.39M | 970K | 1.10M | 1.36M | 325K | 32.4M | 2.29M | 818K | 133K | 306K | 428K |
| Free Cash Flow | 2.08M | -2.34M | -2.49M | -6.70M | -6.48M | -41.2M | -29.2M | -20.0M | -9.22M | -9.44M | -4.40M |
| Ratios | |||||||||||
| ROE | -28.9% | -12.1% | 19.3% | -23.5% | 2.6% | -20.5% | -47.7% | -72.9% | -231.7% | - | - |
| ROA | -5.1% | -3.3% | 9.6% | -14.3% | 2.1% | -11.7% | -24.0% | -39.6% | -44.1% | -35.4% | -31.2% |
| Net Profit Margin | -5.0% | -3.1% | 7.9% | -18.6% | 12.4% | -163.3% | -210.8% | -233.8% | -245.6% | -115.3% | -132.2% |
| Debt to Equity | 1.96x | 1.33x | 0.32x | 0.28x | 0.03x | 0.37x | 0.53x | 0.76x | 3.17x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DSS Inc dividends
DSS Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jan 5, 2024.
Who owns DSS Inc
- Insiders 59.71%
- Institutions 4.09%
- Public & others 36.20%
- Shares outstanding 10.0M
- Free float 4.05M
DSS Inc company profile
- Company name
- DSS Inc
- Ticker
- DSS.US
- Exchange
- USA Stocks
- Listed since
- Jan 3, 1997
- Sector
- Consumer Cyclical
- Industry
- Commercial Services & Supplies
- Employees
- 102
- Fiscal year end
- December
- Address
- 275 Wiregrass Parkway, West Henrietta, NY, United States, 14586
- Phone
- 585 325 3610
- Website
- dssworld.com
About DSS Inc
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, the company focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and acquires assets and investments in the securities trading and funds management arena, as well as lists and operates as a digital asset on secondary market. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York.
DSS Inc management
5- Mr. Heng Fai ChanExecutive Chairman of the Board · born 1945
- Mr. Jason T. GradyInterim Chief Executive Officer · born 1974
- Mr. Tung Moe Chan BApSc, MBA, MEngPresident & Director · born 1979
- Mr. Todd D. Macko C.P.A.Chief Financial Officer · born 1973
- Travis HeuszelLegal & Corporate Affairs Manager